Not specifiedRegulatory Approvalregulatorymid-term

FDA Submission Overview for ANDA215575 by QILU PHARM HAINAN

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 6:04:05 AM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA215575 by QILU PHARM HAINAN represents a potential shift in market dynamics, as it indicates their intent to enter a competitive landscape. Portfolio teams must evaluate the implications of this entry on existing products and market share. Regulatory context from FDA (FDA TA — ANDA215575) supports the near-term read. Assessment grounded in 17 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry of QILU PHARM HAINAN's product and its implications for competitive positioning. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Not specified, 4 regulatory and 3 competitive items passed relevance filtering for QILU PHARM HAINAN.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. The submission indicates QILU PHARM HAINAN's intent to enter the market, which may impact existing competitors in the same therapeutic area.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA215575 (FDA). Entity match (qilu pharm hainan); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority suggests a typical timeline for approval, but the outcome will influence market access and competitive positioning.

Key Risks

Elevated medium regulatory exposure for QILU PHARM HAINAN could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a new competitor could affect pricing strategies and market share for existing players, potentially leading to revenue fluctuations.
Upside for QILU PHARM HAINAN may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Upside for QILU PHARM HAINAN may improve if The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential market entry of QILU PHARM HAINAN's product and its implications for competitive positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the ANDA review and any subsequent announcements regarding approval timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA215575
FDAhigh relevance
Entity match (qilu pharm hainan); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Nociception Phenotype in Individuals With Intellectual Disability
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Ferric Carboxymaltose for Mylan's ANDA217076
Humanexa Signalsmedium relevance
Moderate corpus alignment

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

QILU PHARM HAINAN
existing competitors
market for the therapeutic area

Commercial impact

medium

The entry of a new competitor could affect pricing strategies and market share for existing players, potentially leading to revenue fluctuations.

Regulatory impact

medium

The standard review priority suggests a typical timeline for approval, but the outcome will influence market access and competitive positioning.

What to watch

Monitor the progress of the ANDA review and any subsequent announcements regarding approval timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.